NCT04642547View on ClinicalTrials.gov

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Hepatocellular CarcinomaMolecular Targeted Therapy
Interventions
DRUG

Lenvatinib and Gefitinib

"First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.~One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral."

Trial Locations (1)

200127

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT04642547 - Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter